Mydecine Innovations Group, a publicly traded pre-revenue biopharmaceutical company, launched in early 2020 with collaborators and staff members throughout North America and Europe. Mydecine was founded to offer healthcare professionals a variety of better serotonin-modulating medications by developing novel drug families derived from Psilocybin and MDMA.
Director, President & CEO
David Joshua Bartch is Director, President & CEO of Mydecine Innovations Group. Mr. Bartch's entrepreneurial career took off in 2009 when he co-founded AudioTranscriptionist.com and founded the Denver based dispensary, Doctors Orders. Following these ventures, Mr. Bartch founded a boutique investment firm that operated throughout the U.S. and Canadian markets. In 2014, Bartch co-founded Cannabase.io, the USA's most significant legal and sophisticated cannabis wholesale platform. In 2016, Cannabase.io was acquired by Helix TCS.
Chief Scientific Officer
Robert Roscow is the Chief Scientific Officer of Mydecine Innovations Group. He has spent his career looking for valuable medicinal molecules in nature. Mr. Roscow has already leveraged an expertise in genomics, evolution and molecular biology to maximise the industrial production of cannabinoids and their use in a pharmacological context. This work has resulted in multiple patent filings and accolades in publications ranging from Nature to Rolling Stone. Now Mr. Roscow has set his focus on the vast potential for healing present in fungi.
Management Team
Neil Stevenson-Moore is an experienced executive and thought leader in the technology community. He has an impressive track record of driving growth, success and innovation and has worked in both corporate and entrepreneurial environments. Neil is an excellent problem solver and negotiator, able to bridge the gap between stakeholders and technology. He is dedicated, highly motivated and enthusiastic, and is known for developing elegant solutions and creative approaches to challenges. Neil has a strong ability to build teams and promote positive workplace culture, and has successfully raised over $8M from private investors, community partners, and government organizations. He has also developed business agreements that produce ‘win-win’ results as well as customer-focused product design and technology development across multiple platforms. Neil holds a Bachelor of International Politics from Princeton University and has additional coaching certifications. He is fluent in French and proficient in Spanish. In his free time, Neil enjoys athletics and even played professional hockey for the Edinburgh Capitals.
Novum Securities Limited
2nd Floor, 7-10 Chandos Street, London, W1G 9DQ
BF Borgers CPA PC / BF Borgers CPA PC
Address 5400 W Cedar Av., Lakewood, Colorado, 80226, United States of America T: +1 (303) 953-1454 F: +1 (303) 945-7991 contact@bfbcpa.us
Endeavor Trust Corporation
Suite 702 - 777 Hornby St., Vancouver, British Columbia, V6Z 1S4, Canada T: +1 (604) 559-8880 F: +1 (604) 559-8908 admin@endeavortrust.com
Link Group
10th Floor, Central Square, 29 Wellington Street, Leeds, LS1 4DL, United Kingdom
Principal jurisdiction: British Columbia.
Reporting jurisdiction(s): Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Prince Edward Island, Québec, Saskatchewan
Suite 1890 – 1075 West Georgia Street
Vancouver, BC, V6E 3C9
Copyright © 2024 Mydecine Innovations Group - All Rights Reserved.